Table 3. Principal ongoing trials in neoadjuvant HER2-positive gastric or gastroesophageal cancer.

TRIAL	REGIMEN		PHASE	PRIMARY ENDPOINT
	Experimental Arm	Control Arm
HERFLOT NCT01472029	5-FU + Leucovorin + Oxaliplatin + Docetaxel + Trastuzumab 6 mg/kg iv loading dose, followed by 4 mg/kg iv every 2 weeks	5-FU + Leucovorin + Oxaliplatin + Docetaxel	II	pCR
PETRARCA NCT02581462	5-FU + Leucovorin + Oxaliplatin + Docetaxel + Trastuzumab 8 mg/kg iv loading dose, followed by 6 mg/kg iv every 3 weeks +Pertuzumab 840 mg every 3 weeks	5-FU + Leucovorin + Oxaliplatin + Docetaxel	II/III	pCR/PFS
INNOVATION NCT02205047	5-FU/Capecitabine + Cisplatin + Trastuzumab/Pertuzumab	5-FU/Capecitabine + Cisplatin	II	pCR
TOXAG NCT01748773	RT at Total dose of 45 Gy divided into 25 doses +Capecitabine + Oxaliplatin + Trastuzumab 8 mg/kg iv loading dose, followed by 6 mg/kg iv every 3 weeks	//	II	Safety
RTOG 1010 NCT01196390	RT + Paclitaxel + Carboplatin + Trastuzumab	RT + Paclitaxel + Carboplatin	III	DFS

5-FU: 5-fluorouracil, OS: overall survival, PFS: progression-free survival, RT: radiotherapy, iv: intravenous, pCR: pathological complete response, DFS: disease free survival.